Mosunetuzumab in DLBCL Shows Promise as Frontline Option for Elderly Patients

(MedPage Today) — At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating mosunetuzumab (Lunsumio) as first-line monotherapy for elderly patients with diffuse large B-cell lymphoma…